Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.
[Imugene]
Sorry, but the selected Zotpress account can't be found.
